Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 06 2024 - 4:30PM
Business Wire
Azitra, Inc. (NYSE American: AZTR), a precision dermatology
company announced that it announced today that Travis Whitfill,
COO, will present an overview of the Company at the H.C. Wainwright
23rd Annual Global Investment Conference, being held from September
9-11, 2024. Company management will also be participating in
one-on-one meetings during the conference.
The on-demand presentation will be available for viewing
beginning September 9 at 7:00 a.m. ET. An archived replay of the
presentation will be available on the Company’s website immediately
following the conference and for at least 30 days thereafter.
H.C. Wainwright 26th Annual Global Investment Conference –
September 9-11, 2024
Format: Azitra Inc., Corporate Presentation
Date/Time: Available on-demand Monday, September 9, 2024 at 7:00
AM ET
Participant: Travis Whitfill, Chief Operating Officer
Location: Lotte New York Palace Hotel, New York City, NY
Webcast Link: Here
About Azitra, Inc.
Azitra, Inc. is an early-stage clinical biopharmaceutical
company focused on developing innovative therapies for precision
dermatology using engineered proteins and topical live
biotherapeutic products. The Company has built a proprietary
platform that includes a microbial library comprised of
approximately 1,500 unique bacterial strains that can be screened
for unique therapeutic characteristics. The platform is augmented
by artificial intelligence and machine learning technology that
analyzes, predicts, and helps screen the Company's library of
strains for drug like molecules. The Company's initial focus is on
the development of genetically engineered strains of Staphylococcus
epidermidis, or S. epidermidis, which the Company considers to be
an optimal therapeutic candidate species for engineering of
dermatologic therapies. For more information, please visit
https://azitrainc.com/.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. These statements may be identified by words such
as "aims," "anticipates," "believes," "could," "estimates,"
"expects," "forecasts," "goal," "intends," "may," "plans,"
"possible," "potential," "seeks," "will," and variations of these
words or similar expressions that are intended to identify
forward-looking statements. Forward-looking statements are based on
the Company’s current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict.
Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
These and other risks and uncertainties are described and
incorporated by reference more fully in the section titled “Risk
Factors” in our Form 10-Q filed with the SEC on August 12, 2024.
Azitra explicitly disclaims any obligation to update any
forward-looking statements except to the extent required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240906297209/en/
Investor Relations Contact: Norman Staskey Chief
Financial Officer staskey@azitrainc.com
Hayden IR James Carbonara (646) 755-7412 james@haydenir.com
Azitra (AMEX:AZTR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Azitra (AMEX:AZTR)
Historical Stock Chart
From Oct 2023 to Oct 2024